Home » Topics » Regulatory » EMA

EMA
RSS

EMA recommends that Clinuvel's Scenesse be approved for EPP

Oct. 27, 2014

EMA committee backs approval of olaparib in BRCA-mutated ovarian cancer

Oct. 27, 2014

CHMP recommends expanding approval of enzalutamide

Oct. 27, 2014

CHMP adopts positive opinion for oxycodone/naloxone in RLS

Oct. 27, 2014

EMA outlines recent efforts to expedite development of Ebola treatments

Oct. 23, 2014

EMA grants orphan drug designation to Epidiolex for Dravet syndrome

Oct. 22, 2014

EMA grants orphan drug designation to isactuzumab govitecan

Oct. 21, 2014

Lymphoseek recommended by CHMP for sentinel lymph node detection

Sep. 30, 2014

EMA committee recommends approval of Rezolsta, announces darunavir label extensions

Sep. 30, 2014

Boehringer Ingelheim's nintedanib receives positive opinion for second-line therapy of NSCLC

Sep. 29, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...